

# reach-c

Real world efficacy of antiviral therapy in chronic hepatitis C

Dr Jasmine Yee



## Disclosures

None

## Rationale

- DAAs have led to a major paradigm shift in the assessment and initiation of therapy for HCV
- Australia is one of the first countries globally to provide universal access to government-subsidised DAA therapy
- Large proportion of DAA prescribing is occurring outside of traditional treatment settings

### **Objective:**

To evaluate DAA treatment outcomes from this unique model

---

3

## Study design

- National observational cohort of 17 diverse clinical services
- Consecutive individuals commencing treatment with DAAs from 1 March 2016
- **Efficacy of treatment:** proportion of individuals with undetectable HCV RNA 12 weeks post-treatment (SVR12)

---

4

UNSW  
KIRKSTON

## REACH-C Clinics


State	Clinic	n	Location	Setting
NSW	Asquith Medical Centre	24	Sydney	●
	Dubbo Community Health Centre	157	Dubbo	●
	East Sydney Doctors	61	Sydney	●
	Kirkeaton Road Centre	214	Sydney	●
	Langton Centre	61	Sydney	●
	Matthew Talbot Hostel	28	Sydney	●
	Prince St Medical Centre	136	Orange	●
	Shoalhaven Hospital	217	Shoalhaven	● ●
	St Vincent's Hospital	690	Sydney	● ●
	The Albion Centre	102	Sydney	●
	The Byrne Surgery	36	Sydney	●
	Toormina Medical Centre	60	Coffs Harbour	●
QLD	Cairns and Hinterland HHS	895	Cairns	● ● ● ● ● ● ●
SA	Royal Adelaide Hospital	237	Adelaide	● ●
	The Queen Elizabeth Hospital	651	Adelaide	● ● ● ● ● ● ●
VIC	Scope Gastroenterology	390	Melbourne	●
	University Hospital Geelong	264	Geelong	●

- specialist liver clinic
- drug & alcohol service
- sexual health clinic
- community health clinic
- general practice
- prison

5


UNSW  
KIRKSTON

## Baseline characteristics (n=4223)




6

UNSW KIRKPATRICK  
**Treatment uptake**



7


UNSW KIRKPATRICK  
**Treatment uptake by regimen and duration**



8

UNSW  
KIRKPATRICK


## Treatment uptake by baseline characteristics



9


UNSW  
KIRKPATRICK

## Treatment uptake by baseline characteristics




10

# Overall DAA efficacy




# DAA efficacy by baseline characteristics

Per protocol analysis



## DAA efficacy by genotype


*Per protocol analysis*



13


## DAA efficacy by clinic setting

*Per protocol analysis*




14

## Missing SVR12 by baseline characteristics



15

## Missing SVR12 by clinic setting



16



## Conclusion

- DAA treatment response is high in a diverse population and across a broad range of treatment services
- There was minimal documented virological failure and reinfection
- Missing data presents a real-world challenge, highlighting the need for innovative strategies to retain patients in post-treatment care

17

## Acknowledgements

### Kirby Institute

Prof Greg Dore  
A/Prof Gail Matthews  
Dr Behzad Hajarizadeh  
Dr Marianne Martinello  
Pip Marks  
Joanne Carson

### Principal Investigators

Dr Josh Hanson  
Dr David Iser  
Dr Phil Read  
Dr Annie Balcomb  
A/Prof David Shaw

Dr Renjy Nelson  
Dr John Faros  
A/Prof Jeff Post  
Dr Richard Hallinan  
Dr Amanda Wade  
Gail Snelgar  
Dr David Baker  
Dr William Pratt  
A/Prof Mark Douglas  
Dr Lucy Cooper  
Dr John Smart  
Dr Trish Collie

### Site Staff

Catherine Ferguson  
Jeff Stewart  
Dr Mark Danta  
Becky Hickey  
Dr Christine Roder  
Dr Darren Russell  
Penny Fox  
Carla Gorton  
Rhondda Lewis  
Karen Chronister  
Rachel Deacon  
Ed Hall  
Annie Smoker

Raghib Ahmad  
Brit Johnson  
Melissa Benson  
Arlene Everson  
Susan Holdaway  
Belinda Watson  
Pat Bindley



Australian Government  
Department of Health

18